ArticleJournal of paediatrics and child health2026
Evaluation of a Clinical Risk Score for Preterm Necrotising Enterocolitis: The 'Check-NEC Score'.
Article in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimEarly prediction of necrotising enterocolitis (NEC) in preterm infants is important given its significant health, economic and social-emotional burden. We aimed to validate a clinical risk score (Check-NEC Score [CNS]) for this purpose in preterm infants.
methodsA case-control study was conducted using data (January 2020-December 2023) from very preterm infants (VP: gestation < 32 weeks) with confirmed NEC≥Stage II. CNS was calculated for cases and controls (matched for key confounders) at baseline (T1), 7 days (T2), and 72 h (T3) before NEC diagnosis. Receiver operating characteristic (ROC) analysis was used to determine the sensitivity, specificity, and area under the curve (AUC).
resultsTwenty-two cases of NEC≥Stage II diagnosed at a median (IQR) age of 17 (11-24) days were matched with 22 controls. Median CNS was significantly higher in cases compared to controls at T2 (8 vs. 7, p = 0.025) and T3 (8 vs. 7, p = 0.005). T3 CNS had the highest AUC (0.64, 95% CI 0.48-0.81). A cut-off score of ≥ 11 at T2 had the highest specificity (95%, 95% CI 75%-99%). At T3, a cut-off score of either ≥ 8 or ≥ 9 was best.
conclusionCNS demonstrated acceptable predictive ability at 72 h with high specificity 7 days before NEC diagnosis, depending on the cut-off score chosen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.